📢 RITA-MI2 Partners met last Thursday 29th August in beautiful London for their annual meeting to take stock of the project 3 years after its launch. 🌍👩⚕️👨⚕️ A great opportunity for participants from all across Europe to discuss and plan the next 12 months...
Regulatory approval has now been obtained for all participating coutries.✔️ Since the beginning of the RITA-MI2 trial in 2022, 20 recruitment centres, in France, the UK, Germany, Spain and the Czech Republic have opened for recruitment. 👏 4 additional centres, in...
📢The RITA-MI2 project Second Annual Meeting took place on Wednesday 21st June 2023, on-line. 🖥📆📊 A great opportunity for the 25 participants from all across Europe to discuss about the project’s progress, 2 years after its launch. 🏥💗🩺👩⚕️👩🔬🧪🔜 LinkedIn posts here and...
The RITA-MI2 project First Annual Meeting took place on Tuesday 21st June 2022, on-line. 🖥📆📊 23 project members working for one of the 13 project partners gathered one afternoon to present and discuss about the project’s first year and the next steps to be taken...
The RITA-MI2 trial is listed on clinicaltrials.gov, under registration number NCT05211401. Study Description Brief Summary The main objective is to compare the effect of a single injection of two doses of rituximab versus placebo on 6 months left...
